The positive preliminary revenue figures for both Q4 and the full year 2023 suggest that 10x Genomics is performing better than analysts expected, which is likely to instill confidence in investors and could lead to a short-term increase in the stock price. The announcement directly pertains to the company's financial health and future outlook, making it highly relevant and important to investors.